Human Health

Modern biotechnology provides breakthrough products and technologies to combat debilitating diseases. Innovative medicines and cures help people lead longer, healthier lives and positively impact society by providing economic value far beyond their cost. To ensure these transformative therapies get to the people who need them, BIO is committed to advancing policies that foster innovation, fuel investment and encourage the entrepreneurial spirit that has made America the global leader in this cutting-edge field.

Tears of Sorrow, Tears of Joy

Insights

COVID-19 Pandemic, Two Years Later

Biotech Sector Unites to Aid Ukraine

To improve cardiovascular disease outcomes, connection with community is everything

News

Browse all news

New BIOSECURE bill "reinforces the national security imperative of the biotechnology industry"

May 9, 2024

BIO Comments to the Minnesota Department of Health on Drugs of Substantial Public Interest: Draft Methodology for Public Comment

May 9, 2024

BIO Comments to HHS's Centers for Medicare & Medicaid Services in response to their Information Collection Request (ICR) on the Part C and Part D Medicare Prescription Payment Plan

April 19, 2024

BIO Statement to the Senate 340B Bipartisan Working Group on Safeguarding and Strengthening 340B

April 1, 2024

Letters, Comments & Testimony

BIO Comments to the Minnesota Department of Health on Drugs of Substantial Public Interest: Draft Methodology for Public Comment

May 9, 2024

BIO submits comments on the MDH’s proposed regulations regarding Drugs of Substantial Public Interest: Draft Methodology for Public Comment as required in statute by the Prescription Drug Price Transparency Act.

BIO Comments to HHS's Centers for Medicare & Medicaid Services in response to their Information Collection Request (ICR) on the Part C and Part D Medicare Prescription Payment Plan

April 19, 2024

The Biotechnology Innovation Organization appreciates the opportunity to comment on the Center for Medicare and Medicaid Services’ Information Collection Request on the Part C and Part D Medicare Prescription Payment Plan Model Documents.

BIO Statement to the Senate 340B Bipartisan Working Group on Safeguarding and Strengthening 340B

April 1, 2024

In response to the 340B Request for Information issued by the Senate 340B Bipartisan Working Group, BIO submits detailed comments.

Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.

Join BIOAction

BIO Advocacy Toolkit

We’ve made it easier for you to access information and share content about biotechnology and prescription medicines. Learn more about dozens of topics and then share information you discover on Twitter, Facebook, and LinkedIn.

Discover More